Welcome to our dedicated page for Lifeloc Technologies SEC filings (Ticker: LCTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lifeloc Technologies, Inc. filings document a Colorado operating company that reports as an SEC registrant and trades common stock under LCTC. Its Form 8-K reports furnish operating results, Regulation FD releases, and material-event disclosures tied to the company’s breath alcohol and drug detection device business.
The filing record also covers material financing agreements, debt terms, security interests, capital-structure matters, and the use of proceeds for continued SpinDetect™ product development. Proxy materials describe annual shareholder voting matters, director elections, auditor ratification, governance procedures, and common-stock ownership information.
Lifeloc Technologies director Michael Kornelsen increased his stake through a small open-market purchase. On June 16, 2026, he bought 100 shares of common stock at $2.50 per share. After this transaction, he directly owns 1,100 shares and has indirect beneficial ownership of 27,500 shares held by EDCO Partners LLLP.
Lifeloc Technologies CEO and President Wayne Willkomm reported an open-market purchase of common stock. He bought 1,300 shares of Lifeloc Technologies, Inc. at $2.50 per share. After this transaction, he directly owns 41,625 common shares.
The filing also shows an indirect holding of 23,477 common shares that are beneficially held by EDCO Partners LLLP on his behalf. This Form 4 primarily updates the market on his current direct and indirect ownership in Lifeloc Technologies (LCTC).
Lifeloc Technologies is advancing its SpinDetect™ Centrifugal Drug Analyzer from development into validation and early production. The company has completed production tooling for SpinDetect consumable disks, produced and tested first-article disks, made minor mold fixes, and commissioned a cleanroom with an automated reagent-dispensing robot.
Lifeloc plans a staged rollout, first targeting U.S. forensic and certain international markets, with U.S. workplace use following FDA clearance. The initial product will be a qualitative pass/fail delta-9-THC test, with quantitative and multi-drug panels to follow. The SpinDetect reader is expected to list at about $7,495 in the U.S.
Management highlights the system’s focus on measuring psychoactive delta-9-THC separately from inactive metabolites, which they view as a competitive differentiator for roadside and workplace testing. The company is also investing in its core breath alcohol L-series platform, including an OIML-variant of the LX9 device to broaden international reach and improve manufacturing costs.
Lifeloc Technologies, Inc. reported that Assure CPA, LLC resigned as its independent registered public accounting firm on June 3, 2026, after selling substantially all of its assets to Sadler, Gibb & Associates, LLC and ceasing public accounting operations. Assure’s audit reports for 2024 and 2025 contained no adverse opinions, and the company reports no disagreements or reportable events under Regulation S-K.
The company also summarized results of its June 3, 2026 annual meeting. Shareholders elected five directors, ratified the appointment of Assure CPA as independent auditor for fiscal 2026, approved an advisory say-on-pay vote on executive compensation, and adopted Amended and Restated Articles of Incorporation.
Lifeloc Technologies reported first quarter 2026 net revenue of $2.294 million and a net loss of $152,713, or $(0.06) per diluted share. Revenue grew about 1% from the prior year period, while the loss narrowed from $292,686 as gross margin improved to 43% from 40%.
Research and development remained significant at more than 18% of revenue, largely funding the SpinDetect™ Centrifugal Drug Analyzer. The company completed disk production tooling and received first article disks, described as the last enabling step before beta testing. Cash stood at $569,330 as of March 31, 2026, with total assets of $6.74 million.
In May 2026, Lifeloc closed a $500,000 loan from its Chairman and CFO at 10.5% interest, adjustable with prime, with interest-only payments in 2026 and a five-year repayment schedule and no prepayment penalty.
Lifeloc Technologies reported first-quarter 2026 revenue of $2,293,812, up about 1% year over year, driven by slightly higher product sales. Gross profit rose to $987,074, with product gross margin improving to 43% from 40% as cost of sales declined.
The company still posted a net loss of $152,713, but this was narrower than the $292,686 loss a year earlier, with lower research, development, and sales and marketing expenses helping offset higher interest costs. Cash and cash equivalents were $569,330 at March 31, 2026, versus current liabilities of $1,064,101, leaving a modest liquidity cushion.
Lifeloc continues to depend on its core breathalyzer business while investing heavily in its SpinDetect™ drug-detection platform, which it aims to launch commercially in 2026. After quarter-end it added a $500,000 secured loan from its CFO and Board Chairman at 10.5% interest to support development, increasing reliance on related-party financing and leverage.
Lifeloc Technologies, Inc. entered into a related-party loan transaction with its Chief Financial Officer and Chairman, Vern Kornelsen. The company issued a $500,000 Promissory Note dated May 1, 2026 to fund continued development of its SpinDetect™ product.
The Note carries an initial interest rate of 10.5% per annum, with interest-only payments through December 31, 2026. Starting January 31, 2027, it converts to sixty equal monthly payments of principal and interest, with final maturity on December 31, 2031, and an interest rate that may increase with changes in the prime rate.
The Note may be prepaid at any time without penalty and is secured by a Deed of Trust on Lifeloc’s principal office at 12441 West 49th Avenue, Wheat Ridge, Colorado, and by a security interest in substantially all company assets, both subordinated to existing senior indebtedness to Citywide Banks.
Lifeloc Technologies, Inc. is asking shareholders to approve several items at its June 3, 2026 annual meeting, including electing five directors, ratifying Assure CPA as auditor and holding an advisory “Say on Pay” vote on executive compensation.
A key proposal would adopt Amended and Restated Articles of Incorporation that both consolidate prior amendments and add a new foreign ownership provision. The board could redeem shares held by holders reasonably determined to be nationals or entities of U.S. Department of Energy “countries of risk,” at fair market value based on a 30‑day average closing bid price, after written notice and a 90‑day cure opportunity.
The proxy also details board and committee structure, director independence, modest director fees of $1,530 each for 2025, and 2025 executive pay, including total compensation of $302,518 for the CEO and $97,920 for the CFO, alongside a pay‑versus‑performance table showing recent net losses.
Lifeloc Technologies reported full-year 2025 revenue of $9.027 million, up 6% from $8.538 million in 2024, as demand for its breath alcohol testing products grew modestly while gross margin held essentially flat at 40.3%.
The company recorded a net loss of $2.470 million, or $(0.90) per diluted share, compared with a net loss of $1.053 million, or $(0.41), in 2024. Management explains the wider loss mainly reflects a non-cash increase in the deferred tax valuation allowance to $1.738 million, driven by recent loss history. Excluding this accounting change, loss before taxes improved slightly to $1.311 million from $1.405 million.
Cash and cash equivalents declined to $746,001 at December 31, 2025 from $1.244 million, with operating activities using $499,319 of cash and continued investment in property and R&D equipment. Total assets were $6.69 million and stockholders' equity was $4.10 million, down from $6.23 million a year earlier.
Lifeloc Technologies, Inc. reports its annual business update, highlighting steady breathalyzer operations and major investment in a new drug-testing platform. Product sales reached $8,958,672 in 2025, up 6% from 2024, with total revenues of $9,026,938. The company remains focused on fuel cell breathalyzers for law enforcement, workplace, corrections, OEM and international markets, now fully occupying its Wheat Ridge, Colorado headquarters after discontinuing a rental-property segment.
A key strategic initiative is SpinDetect™, a centrifugal microfluidic “lab-on-a-disk” system for rapid, quantitative drugs-of-abuse testing, including delta-9-THC. Lifeloc spent $2,152,843 on research and development and sustaining engineering in 2025 and added $354,381 of SpinDetect-related equipment, targeting an initial commercial launch in 2026. Management notes that continued progress will depend on access to capital, while also carrying subordinated debentures totaling $825,000 at 8.25% and a $1,350,000 mortgage maturing in 2031.